Aquestive Therapeutics Announces Proposed Public Offering of Common Stock
WARREN, N.J., Dec. 10, 2019 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (Nasdaq: AQST) (“Aquestive”), a specialty pharmaceutical company focused on developing and commercializing
differentiated products based on its proprietary PharmFilm technology to meet patients’ unmet needs and solve therapeutic problems, today announced that it intends to offer and sell $35 million of
shares of its common stock in an underwritten public offering. In connection with this offering, Aquestive expects to grant the underwriters a 30-day option to purchase up to an additional $5.25
million of shares of common stock at the public offering price, less the underwriting discount. The offering is subject to market conditions, and there can be no assurance as to whether or when the
offering may be completed, or as to the actual size or terms of the offering. All of the shares in the offering are being offered by Aquestive.
BMO Capital Markets is acting as sole book-running manager for this offering.
Aquestive intends to use the net proceeds of this offering for the continuation of the commercial launch of Sympazan, preparations to support the expected launch of its product candidate Libervant in late 2020 (if approved by the US Food and Drug Administration (the “FDA”)), continued development of AQST-108 and other product candidates, working capital and general corporate purposes.
The securities described above are being offered by the Company pursuant to a shelf registration statement previously filed with the Securities and Exchange Commission (the “SEC”) and declared effective by the SEC on September 17, 2019 only by means of a prospectus supplement and accompanying prospectus included in the registration statement. A preliminary prospectus supplement and the accompanying prospectus relating to the securities being offered will be filed with the SEC and will be available on the SEC’s website at http://www.sec.gov. When available, copies of the preliminary prospectus supplement and the accompanying prospectus relating to the securities being offered may also be obtained from BMO Capital Markets Corp., 3 Times Square, New York, NY 10036, Attention: Equity Syndicate Department, Telephone: (800) 414-3627, Email: firstname.lastname@example.org.